Launched the very first issue of the IRRDC Newsletter, which contains recent research highlights and articles written by members of our team and global family.
Held our inaugural education night, on April 1st, 2021. This is part of an ongoing education series aimed at sharing our work with patients, families and collaborators.
As of 2021, we have published more than 35 papers on the treatment and management of RRD cancers.
We published new papers about novel therapies for patients with hypermutant cancers, that show the first objective long-term survival responses.
2017 and 2021
In 2017 and 2021, we launched two successful international clinical trials at 21 hospitals in 5 countries.
We published our discovery of MS-sigs, which are cheaper and easier tools to diagnosis CMMRD, so that all patients throughout the world can access better care.
We increased our breadth to include all forms of Replication Repair Deficiency and changed our name to the International RRD Consortium.
We established our patient advocacy group to ensure that the needs of patients and their families were incorporated into our research.
We held our first international workshop, which brought together scientists, clinicians and researchers from more than 18 countries.
Between 2010 and 2017, our consortium grew by 241% compared to previous years, as efforts to increase awareness of this syndrome lead to an increase in the number of global collaborations and patients with CMMRD identified.
The CMMRD Surveillance protocol was established and the consortium began to prospectively follow patients to assess its efficacy. In 2021, we published a paper showing that the surveillance protocol dramatically improved patient survival